Welcome : Guest

GENETIC TESTING - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Genetic Testing in US$ Million. The US market is further analyzed by the following Segments: Prenatal & Newborn Genetic Testing, Pharmacogenomic Testing, and Predictive Diagnostics. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 88 companies including many key and niche players such as -

23andMe, Inc.
Abbott Laboratories
AutoGenomics, Inc.
Biocartis NV
BioRad Laboratories

Click here to request a full list of companies covered in the report...

Code: MCP-1392
Price: $4950
Companies: 88
Pages: 408
Date: May 2017
Market Data Tables: 60
  Status: * New Report



TABLE OF CONTENTS


  GENETIC TESTING (Complete Report) Pages : 408   | $4950

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   A Curtain Raiser.....II-11$100
   Top Ten Genetic Disorders Worldwide.....II-21$100
   Genetic Testing: Heralding a New Era.....II-31$100
   Genetic Testing Paves the Way for Personalized Medicine.....II-4
Table 1: Drug Ineffectiveness for Select Therapeutic Categories - Necessitating Personalized Medicine (includes corresponding Graph/Chart).....II-4
1$350
   Genetic Testing – A Critical Part of the Rapidly Developing In-Vitro Diagnostics (IVD)
  Market.....II-5
Table 2: Global In Vitro Diagnostics (IVD) Market by Geographic Region (2016): Percentage Breakdown of Revenues for Asia-Pacific; Europe, Middle-East and Africa; North America; and Latin America (includes corresponding Graph/Chart).....II-5
1$350
   Table 3: Global In-Vitro Diagnostics Market by Sector (2016): Percentage Breakdown of Revenues for Hospital & Commercial Laboratories, and Decentralized & Patient Self-Testing (includes corresponding Graph/Chart).....II-6

Table 4: Leading Players in the Global In Vitro Diagnostics Market (2016): Percentage Breakdown of Revenues for Abbott, Beckman Coulter, Roche, Siemens, Thermo Fisher and Others (includes corresponding Graph/Chart).....II-6
Genetic Testing: The Rapidly Growing Segment of Molecular Diagnostics Market.....II-6
1$350
   Table 5: Global Molecular Diagnostics Market (2016): Percentage Breakdown of Revenues for Blood Donor Screening, Genomics and Infectious Disease Testing (includes corresponding Graph/Chart).....II-7
An Overview of Current Technologies in Genetic Testing.....II-7
1$350
   Table 6: Global Genetic Testing Market by Technology (2016 & 2024): Percentage Breakdown of Revenue for Hybridization, Microarray, NGS and PCR (includes corresponding Graph/Chart).....II-8
Biomarker Discovery Leads to Advanced Genetic Testing.....II-8
1$350
   List of US-FDA Approved Biomarkers for Cancer.....II-91$100
   Ballooning Global Population Offers Increased Growth Opportunities.....II-10 1$100
   Table 7: Top 25 Countries Worldwide in Terms of Population: 2015 & 2016 (includes corresponding Graph/Chart).....II-11
Aging Population Drives the Genetic Testing Market.....II-11
1$350
   Table 8: Global Population Statistics for the 65+ Age Group (2015) (includes corresponding Graph/Chart).....II-121$350
   Table 9: Comparison of Aging Population by Country (1980, 2015 & 2050): Percentage Share of Population Aged Above-65 Years of the Overall Population for Select Countries (includes corresponding Graph/Chart).....II-131$350
   Table 10: Life Expectancy for Select Countries in Number of Years: 2015E (includes corresponding Graph/Chart).....II-141$350
   Improving Healthcare Expenditure to Drive Demand.....II-15 1$100
   Table 11: Healthcare Spending as % of GDP by Region (2016E) (includes corresponding Graph/Chart).....II-16

Table 12: Per-Capita Healthcare Expenditure in US$ for Select Countries/Regions (2014) (includes corresponding Graph/Chart).....II-16
1$350
   Competitive Overview.....II-171$100
   Prenatal Testing Market to Rise.....II-18
List of Genetic Disorders by Event, Genetic Manifestation and Prevalence.....II-18
1$100
   Prenatal Testing – Changing the World of Pregnancy Care.....II-19
Prenatal Testing – A Rudimentary Overview.....II-19
List of Available Prenatal Screening and Diagnostic Tests by Indication.....II-19
1$100
   Conventional Invasive Pre-Natal Diagnostic Techniques – A Risky Affair.....II-20
Other Negativities of Existing Invasive Techniques.....II-20
Emergence of Non-Invasive Prenatal Diagnosis (NIPD).....II-20
1$100
   US Leads in NIPD Market.....II-21
Competition Intensifies in the NIPD Market.....II-21
1$100
   Commercially Available NIPD (Genetic) Tests for Aneuploidy in the US.....II-22
NIPD Eliminates Risks and Uncertainty of Conventional Diagnostic Procedures.....II-22
Opposition to NIPD Technique – A Significant Hurdle to Adoption.....II-22
1$100
   Benefits Outweigh Snags in NIPD Tests.....II-23
Major Factors Influencing Penetration of NIPD Tests.....II-23
1$100
   Table 13: Price Comparison of Existing Tests and Screening Procedures for Down’s Syndrome.....II-24
Diversity in NIPD Usage on the Cards.....II-24
Expanded Newborn Screening.....II-24
1$350
   Technological Advancements Boost Prenatal Genetic Screening Market.....II-25
CMA Stakes Claim as the First-Line Test in Fetal Abnormalities; Issues Hinder
  Growth.....II-25
1$100
   Strain on Resources Prevent Wide Adoption of Expanded Carrier Sequencing.....II-26
Fetal Diagnostic WES – A Promising Advancement in Prenatal Screening.....II-26
1$100
   Predictive Diagnostics.....II-27
Breast Cancer Gene Testing Market to Expand Strongly.....II-27
Myriad Genetics – The Unquestioned Leader in Breast Cancer Testing.....II-27
1$100
   Routine Clinical Testing Vs. Predictive Genetic Testing.....II-281$100
   Increasing Incidence and Prevalence of CDDs: A Major Growth Driver.....II-29
Discovery of Novel Biomarkers Crucial to Predictive Diagnostics.....II-29
1$100
   Unresolved Issues Hamper Widespread Implementation of Genetic Diagnosis and
  Testing for Monogenetic Disease.....II-30
Dearth of Genetic Counselors – A Major Hurdle for the Predictive Genetic
  Testing.....II-30
1$100
   Pharmacogenomics Development Augurs Growth of Genetic Testing Market.....II-311$100
   Direct-to-Consumer Genetic Testing – A Key Trend in the Genetic Testing Market.....II-32
Direct-to-Consumer Genetic Testing is Here to Stay.....II-32
1$100
   Creating a Platform for New Companies.....II-33
Business Models for DTC Genetic Testing Firms.....II-33
Growing Prominence of DTC Genetic Testing: A Boon or a Curse?.....II-33
1$100
   Genetic Screening of Newborns to Rise.....II-34
Pre-implantation Genetic Diagnosis (PGD) - A Major Driver for the Genetic Testing
  Market.....II-34
Whole Genome Sequencing – Boon or Bane to Genetic Testing?.....II-34
1$100
   Utility of Genetic Testing for Warfarin Study.....II-35
As Technologies Grow, Need for Better Interpretation of Tests Increases.....II-35
1$100
   Selling Collected Patient Genetic Information Becomes a New Business.....II-361$100
   Oncology – A Key Focus Area for Genetic Testing.....II-37 1$100
   Table 14: World Cancer Incidence by Geographic Region and Gender (2012): Number of New Cancer Cases Reported (in Thousands) for Asia-Oceania, Europe, North America, Latin America & The Caribbean, and Africa (includes corresponding Graph/Chart).....II-381$350
   Table 15: New Cancer Cases in the World by Affected Site (2012) (in Thousands) (includes corresponding Graph/Chart).....II-391$350
   Table 16: Cancer Incidence in Developed Nations by Site: 2012 (includes corresponding Graph/Chart).....II-401$350
   Table 17: Global Incidence of Common Cancers in Men (2012): Number of New Cases Reported in Thousands for Lung & Bronchus, Prostate, Colorectal, and Liver Cancers (includes corresponding Graph/Chart).....II-41

Table 18: Global Incidence of Common Cancers in Women (2012): Number of New Cases Reported in Thousands for Breast, Colorectal, Lung & Bronchus, and Liver Cancers (includes corresponding Graph/Chart).....II-41
1$350
   Table 19: World Cancer Mortality by Geographic Region and Gender (2012): Number of Cancer-Related Deaths (in Thousands) for Asia-Oceania, Europe, North America, Latin America & The Caribbean, and Africa (includes corresponding Graph/Chart).....II-421$350
   Liquid Biopsy to Change the Face of Cancer Diagnosis and Treatment.....II-43
Genetic Testing May Aid CNS Disease Therapeutics.....II-43
1$100
   Neurodegenerative Diseases - Major Focus Area for Genetic Testing.....II-44
Alzheimer’s Disease.....II-44
1$100
   Validity of Emerging Genetic Tests for Alzheimer’s.....II-45
Newly Developed Test Predicts Age of Onset of Alzheimer’s.....II-45
1$100
   Huntington’s Disease.....II-46 1$100
   Table 20: Global Prevalence of Huntington’s Disease by Geographic Region (includes corresponding Graph/Chart).....II-471$350
   Genetic Testing – An Indispensable Tool for Cystic Fibrosis.....II-48 1$100
   Table 21: Most Common Mutations and Worldwide Frequency (includes corresponding Graph/Chart).....II-49
Histocompatibility Testing.....II-49
1$350
   Next-Generation Sequencing – A Giant Leap in Genome Sequencing.....II-50
Pediatric Genetic Testing for Screening Adult Onset Disorders Fast Gaining
  Acceptance.....II-50
Better Regulatory Safeguards Required for Global Genetic Testing Industry.....II-50
1$100
   Challenges Faced.....II-511$100
   Controversial Applications Marr Genetic Testing Market.....II-521$100
   Genetic Counseling: Gaining Momentum.....II-53
Online Approach Gains Momentum.....II-53
Recommendations of ACOG and ACGM Augments Demand for Cystic Fibrosis Testing.....II-53
1$100
   Ethical Issues & Need for Appropriate Regulating Policies.....II-541$100
   Issues Related to Genetic Tests for Obesity.....II-55
Diagnosis and Treatment during Pregnancy - An Effective Way of Alleviating Syphilis
  Related Deaths and Stillbirths.....II-55
1$100
   Global Molecular Diagnostics on a High Growth Curve.....II-56
Automation Driving Global Market.....II-56
Molecular Diagnostics: Marking the Convergence of Numerous Technologies.....II-56
MDx Market for Infectious Diseases Zooming Ahead.....II-56
Aging Population, Disease Incidence – Fundamental Drivers of Growth.....II-56
1$100
   Pharmaceutical Firms Carving Their Niche in Molecular Diagnostics Market.....II-57
Towards Tailoring the Right Treatment for the Right Disease.....II-57
Limited Reimbursements by Third Party Payers – A Stumbling Block.....II-57
1$100
   Disease-Specific Molecular Diagnostics to Deliver Improved Clinical Outcomes.....II-58
Molecular Diagnostics and Intellectual Property.....II-58
Business Opportunities in the Offing.....II-58
1$100
   Medical Training and Practice Challenges.....II-59
Hurdles All the Way for Companies Eyeing Molecular Diagnostics.....II-59
1$100
   Product Marketing – Key to Commercial Success.....II-60
Integration of Molecular Diagnostics into Therapeutics.....II-60
Molecular Diagnostics – Moving from Centralization to Decentralization.....II-60
2$200
   Competitive Landscape of the Molecular Diagnostics Market.....II-62
Table 22: Leading Players in the Global Molecular Diagnostics Market (2016): Percentage Breakdown of Value Sales for Abbott, Cepheid, Grifols, Hologic, Qiagen, Roche and Others (includes corresponding Graph/Chart).....II-62
New Entrants Eye Unmet Needs.....II-62
1$350
   Preface to Genetic Testing.....II-63
Genetic Testing and its Applications.....II-63
1$100
   Gene Candidate and Genome Screen.....II-64
‘DNA Chip’ to Chip into Genetic Field.....II-64
1$100
   Techniques Used to Identify Changes in Genes.....II-65
Types of Genetic Testing.....II-65
Prenatal Diagnosis.....II-65
Cancer Testing.....II-65
1$100
   Carrier Identification.....II-66
Newborn Screening.....II-66
Predictive Testing.....II-66
Pre-Symptomatic Testing.....II-66
Cytogenetic Tests.....II-66
1$100
   Steps in Genetic Testing Process.....II-67
Limitations.....II-67
Risks and Other Limitations of Genetic Testing.....II-67
Medical Institutions to Reap the Benefit of Genetic Testing.....II-67
1$100
   Pharmacogenetics/Pharmacogenomics.....II-68
Review of Select Genetic Tests.....II-68
Cystic Fibrosis.....II-68
Breast and Ovarian Cancer (BRCA).....II-68
Alzheimer's disease.....II-68
Colorectal Cancer.....II-68
1$100
   Haemochromatosis (HH).....II-69
Cowden Syndrome.....II-69
Huntington's disease (HD).....II-69
Costs of Select Tests.....II-69
Table 23: Costs of Select Genetic Tests.....II-69
Genetic Testing Techniques.....II-69
Signal Amplification Technologies.....II-69
PCR – New Developments.....II-69
1$350
   Quantitative Real-Time PCR for Molecular Diagnostics.....II-70
Signal Detection and Quantification.....II-70
1$100
   Quantitative Real-Time RT-PCR Analysis.....II-71
Applications of Quantitative Real-Time PCR Analysis.....II-71
Viral Detection and Viral-Load Monitoring.....II-71
Sensitive Detection of Infectious Disease Agents.....II-71
Predisposition Testing.....II-71
Non-PCR Methods.....II-71
Other Signal Amplification Technologies.....II-71
DNA Probe Based Products.....II-71
1$100
   Direct Detection of Specific Nucleic Acid Sequences.....II-72
Nucleic Acid Amplification and Detection.....II-72
DNA Sequencing and Gene Detection.....II-72
1$100
   Arrays of Immobilized Probes (DNA Chips) in Gene Detection.....II-73
RNA Diagnostics.....II-73
1$100
   AutoGenomics Rolls Out INFINITI® H. pylori Assay.....II-74
23andMe Obtains FDA Approval for Personal Genetic Test for Select Diseases.....II-74
Invitae Adds News Tests to Proactive Genetic Testing Repertoire.....II-74
Thermo Fisher Scientific Launches CarrierScan™ Assay.....II-74
MedGenome Unveils Claria Carrier Screening Test in India.....II-74
Phosphorus Rolls Out Advances Tests for Inherited Conditions.....II-74
Cancer Genetics Launches Genomic Panel for HBOC.....II-74
1$100
   Illumina, Bio-Rad Launch Single-Cell Genomic Sequencing Solution.....II-75
MyHeritage Introduces MyHeritage DNA Service.....II-75
Thermo Fisher Scientific Unveils Clariom Pico Assays.....II-75
IBM Watson Health, Quest Diagnostics Roll Out IBM Watson Genomics.....II-75
Thermo Fisher Scientific Introduces PharmacoScan Solution.....II-75
Good Start Genetics Launches EmbryVu PGS Test.....II-75
Spark Therapeutics Introduces Testing for Inherited Retinal Diseases.....II-75
1$100
   AutoGenomics Launches INFINITI® Buccal Sample Collection Kit.....II-76
FutuTest Launches FERTIFY™ Genetic Test.....II-76
Quest Diagnostics Introduces New Cancer Test Services.....II-76
Good Start Genetics Launches Next-Generation Embryo Screening Solution.....II-76
Invitae Introduces Pediatric Tests for Rare Disease and Pediatric Genetics.....II-76
Contextual Genomics Introduces Cancer Genome Test.....II-76
Transgenomic Introduces CMT NGS Panel.....II-76
Ambry Genetics Rolls Out Suite of Genetic Testing Panels for Epilepsy.....II-76
1$100
   Good Start Genetics Introduces EmbryVu PGS Test.....II-77
23andMe Secures FDA Approval for New Trimmed Down DNA-based Health Analysis.....II-77
Roche Rolls Out Oncology Assay.....II-77
AutoGenomics Launches INFINITI® SMART.....II-77
Transgenomic Rolls Out Transgenomic Leukodystrophy NGS Panel.....II-77
Color Genomics Rolls Out New Test for Cancer-Associated Genes.....II-77
PerkinElmer Launches Genetic Screening Processor® Instruments in China.....II-77
Mayo Clinic Launches Eight NGS Panels for Cardiac Disorders.....II-77
1$100
   Sequenom Laboratories and Recombine Launch HerediT® UNIVERSAL.....II-78
Multipicom NV Launches ADH MASTR™ v2 assay.....II-78
23andMe Launches Drug Development Unit.....II-78
Quest Diagnostics Launches Neurome™ Exome Sequencing Service.....II-78
Roche Launches cobas 6800/8800 Systems.....II-78
Agena Biosciences Launches MassARRAY 24-Well System.....II-78
FDA Grants Marketing Approval to 23andMe’s DTC Bloom Syndrome Carrier Genetic
  Test.....II-78
1$100
   Transgenomic to Launch ICE COLD-PCR™ Technology.....II-79
Rosetta Launches Sequencing-based Oncology Tests by Admera Health.....II-79
MedGenome Labs Launches Panorama Prenatal Test.....II-79
Ambry Genetics Launches CVD Genetic Testing Panels.....II-79
Exceltox Launches Pharmacogenomic Testing.....II-79
PerkinElmer Launches SCID Screening Test in North America.....II-79
Quest Diagnostics Introduces BRCAvantage Plus™.....II-79
1$100
   Genetic Technologies Launches BREVAGenplus Test.....II-80
Sophia Genetics Receives CE-IVD Certification for Genetic Testing.....II-80
Response Genetics Launches Immuno-Oncology Assay.....II-80
DeNA Life Science Launches Mycode Genetic Testing Service.....II-80
Pathway Genomics Launches BRCATrue™ Test.....II-80
Courtagen Launches Genetic Sequencing Tests for Neurodevelopmental Disorders.....II-80
Myriad Genetics Launches EndoPredict® Breast Cancer Test.....II-80
1$100
   Assurex Health Expands GeneSight® Pharmacogenomic Testing Platform.....II-81
Illumina to Launch VeriSeq Embryo Screening Tool.....II-81
GENEWIZ Launches PGxOne™ Pharmacogenomic Test.....II-81
Ambry Genetics Launches ExomeNext™ and ExomeNext-Rapid™ Genetic Tests.....II-81
Pathway Genomics Launches Genetic Test to Detect Risk of Colorectal Cancer.....II-81
Mount Sinai Laboratory Develops Accurate Genetic Test for SMA.....II-81
1$100
   Agilent Inks Deal to Take Over Multiplicom.....II-82
DNA Diagnostics Center Acquires IDENTIGENE.....II-82
Genetic Analysis and Bio-Rad Ink Deal for Transferring Commercialization Rights to
  GA-map™.....II-82
Thermo Fisher Files for PMA Approval of its Oncomine Universal Dx Test.....II-82
LabCorp Takes Over Sequenom.....II-82
WuXi AppTec and AutoGenomics Team Up to Launch Advanced Molecular Diagnostic
  Technology In China.....II-82
1$100
   Danaher to Take Over Cepheid.....II-83
Quest Diagnostics to Offer Genetic Testing Services for Ancestry.....II-83
Transgenomic and LabCorp Sign Commercial License Agreement for TBIO’s DNA
  Susceptibility Testing IP.....II-83
Next Biosciences Merges with Genesis Genetics.....II-83
PerkinElmer Expands Services in India.....II-83
PerkinElmer Takes Over Vanadis Diagnostics.....II-83
AutoGenomics and McKesson to Jointly Distribute INFINITI® Molecular Diagnostic Systems
  and Related Products.....II-83
1$100
   Transgenomic Divests GAP Business.....II-84
Thermo Fisher Teams Up with Novartis and Pfizer for Developing NGS Oncology
  Test.....II-84
NeoGenomics Acquires Clarient.....II-84
MedGenome to Build Data Specific to India for Testing Kits.....II-84
Roche to Take Over Kapa Biosystems.....II-84
Natera Selects DNAnexus Cloud Genomics Platform for its Genetic Tests.....II-84
ESPERITE Acquires InKaryo.....II-84
Transgenomic Signs Agreement with Exiqon A/S.....II-84
1$100
   Quest Diagnostics and Myriad Genetics End BRCA Gene Patent Litigation.....II-85
Roche to Acquire Majority Share of Foundation Medicine.....II-85
Roche Acquires Ariosa Diagnostics.....II-85
GSK Collaborates with GE on Oncology Genetic Testing.....II-85
Cancer Genetics to Acquire Gentris Corporation.....II-85
Natera Partners with Mount Sinai Genetic Testing Laboratory.....II-85
Transgenomic to Sell SURVEYOR Nuclease Technology to Integrated DNA
  Technologies.....II-85
1$100
   Transgenomic Collaborates with Raptor Pharmaceuticals for Genetic Testing
  Services.....II-86
AutoGenomic Signs Agreement with Genomas.....II-86
Cancer Genetics Acquires BioServe Biotechnologies.....II-86
PerkinElmer to Close Its Signature Genomics Testing Business.....II-86
LifeLabs Medical Laboratory Services Buys out Centogene’s Canadian Business.....II-86
CytoScan Dx Assay by Affymetrix Receives FDA Approval.....II-86
1$100
   23andMe, Inc. (USA).....II-87
Abbott Laboratories (USA).....II-87
1$100
   AutoGenomics, Inc. (USA).....II-88
Biocartis NV (Belgium).....II-88
1$100
   BioRad Laboratories (USA).....II-89
Cepheid Inc. (USA).....II-89
1$100
   ELITech Group S.P.A. (France).....II-90
Illumina, Inc. (USA).....II-90
1$100
   Laboratory Corporation of America Holdings (USA).....II-911$100
   Sequenom, Inc. (USA).....II-921$100
   Luminex Corporation (USA).....II-93
Natera, Inc. (USA).....II-93
PerkinElmer, Inc. (USA).....II-93
1$100
   QIAGEN N.V. (The Netherlands).....II-94
Quest Diagnostics, Inc. (USA).....II-94
1$100
   Roche Diagnostics Corp. (Switzerland).....II-951$100
   Roche Molecular Diagnostics, Inc. (USA).....II-96
Thermo Fisher Scientific (USA).....II-96
1$100
   Transgenomic, Inc. (USA).....II-971$100
   Table 24: World Recent Past, Current & Future Analysis for Genetic Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....II-981$350
   Table 25: World Historic Review for Genetic Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-991$350
   Table 26: World 14-Year Perspective for Genetic Testing by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....II-1001$350
   A. Market Analysis.....III-1
The US: Leading Market for Genetic Testing Globally.....III-1
Demographic Changes Offer Growth Opportunities.....III-1
1$75
   Table 27: North American Aging Population by Age Group: 1975-2050 (includes corresponding Graph/Chart).....III-2
Burgeoning Potential for Genetic Testing.....III-2
1$200
   Use of Genomic Data in Clinical Settings to Gather Pace.....III-3
Predictive Screening: Another Growth Area.....III-3
An important Market for Personalized Medicine.....III-3
1$75
   Epidemic Proportion of Cancer in the US – Driver for Cancer Genetic Testing.....III-4 1$75
   Table 28: New Cancer Cases by Gender and Affected Site in the US (2017E) (includes corresponding Graph/Chart).....III-51$200
   Table 29: Cancer Related Deaths by Gender in the US (2017E) (includes corresponding Graph/Chart).....III-61$200
   Newborn Testing Gains Ground.....III-7
Success Stories.....III-7
1$75
   Skepticism Limits Widespread Adoption of Genetic Testing.....III-8
Favorable Reimbursement Policies.....III-8
Favorable Insurance Coverage for Cystic Fibrosis Genetic Testing.....III-8
1$75
   Popularity of Screening and ACOG Guidelines Sink Invasive Prenatal Diagnosis
  Numbers.....III-9
Tough Market Prospects for Sex Determination Tests.....III-9
Coverage of NIPT in Average Risk Pregnancies Expands Target Market.....III-9
1$75
   Wastage from Unnecessary Genetic Testing – A Growing Concern.....III-10
IP Landscape of NIPD Tests.....III-10
1$75
   US Patents of cff DNA-based NIPD Tests.....III-111$75
   Direct-to-Consumer Testing - A Growing Market.....III-12
DTC Genetic Tests Provide POCT for Patients in Hospice Care.....III-12
1$75
   Competitive Overview.....III-13
Myriad Eyes Diversification and Expansion for Growth.....III-13
Natera Holds Fort in the NIPT Market.....III-13
1$75
   Table 30: Leading Players in the US Non-Invasive Prenatal Testing Market (2016): Percentage Breakdown of Revenue for Illumina, LabCorp/Sequenom, Natera, Roche and Others (includes corresponding Graph/Chart).....III-14
Invitae Banks on Low Cost Solutions for Expanding Revenues.....III-14
Regulatory Environment.....III-14
1$200
   Genetic Information Nondiscrimination Act Boosts Genetic Testing.....III-15
Stricter Regulations for DTC Genetic Testing.....III-15
1$75
   H.R. 1313 Bill Rakes New Controversy.....III-161$75
   FDA Attempts to Put a Leash around Unapproved DTC Genetic Tests.....III-17
Negotiated Prices Bring Comfort to Several Diagnostic Companies.....III-17
1$75
   Product Launches.....III-186$450
   Strategic Corporate Developments.....III-244$300
   Select Key Players.....III-289$675
   B. Market Analytics.....III-37
Table 31: The US Recent Past, Current & Future Analysis for Genetic Testing by Segment - Prenatal & Newborn Genetic Testing, Pharmacogenomic Testing, and Predictive Diagnostics Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-37
1$200
   Table 32: The US Historic Review for Genetic Testing by Segment - Prenatal & Newborn Genetic Testing, Pharmacogenomic Testing, and Predictive Diagnostics Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-381$200
   Table 33: The US 14-Year Perspective for Genetic Testing by Segment - Percentage Breakdown of Revenues for Prenatal & Newborn Genetic Testing, Pharmacogenomic Testing, and Predictive Diagnostics Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-391$200
   A. Market Analysis.....III-40
Current & Future Analysis.....III-40
Regulatory Scenario.....III-40
Rising Incidence of Chronic Diseases Spurs Genetic Testing Demand.....III-40
1$75
   Table 34: New Cancer Cases in Canada (2016): Percentage Breakdown of Cancer Incidence by Gender and Affected Site (includes corresponding Graph/Chart).....III-411$200
   Table 35: New Cancer Cases in Canada by Province (2016) (includes corresponding Graph/Chart).....III-421$200
   Table 36: Cancer Incidence in Canada by Age Group and Gender: Age Standardized Incidence Rate per 100,000 People (2015) (includes corresponding Graph/Chart).....III-43
Product Launches.....III-43
Strategic Corporate Development.....III-43
1$200
   B. Market Analytics.....III-44
Table 37: Canadian Recent Past, Current & Future Analysis for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-44
1$200
   Table 38: Canadian Historic Review for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-451$200
   A. Market Analysis.....III-46
Current & Future Analysis.....III-46
Demographics Drive Market Growth.....III-46
Table 39: Japanese Population by Age Group (2017) (includes corresponding Graph/Chart).....III-46
1$200
   DTC Genetic Testing Regulatory Scenario.....III-47
Product Launch.....III-47
1$75
   B. Market Analytics.....III-48
Table 40: Japanese Recent Past, Current & Future Analysis for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-48
1$200
   Table 41: Japanese Historic Review for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-491$200
   A. Market Analysis.....III-50
Market Overview.....III-50
An Insight into Molecular Diagnostics Markets in Europe.....III-50
1$75
   Cancer Trends.....III-51
Table 42: Cancer Incidence in Europe by Site: 2012 (in Thousands) (includes corresponding Graph/Chart).....III-51
1$200
   Aging Population to Drive Demand for Genetic Testing.....III-52
Table 43: Population Breakup by Age Group for Select EU-28 Countries: 2015 (as a Percentage of Total Population) (includes corresponding Graph/Chart).....III-52
1$200
   European Personalized Medicine Market to Exhibit Robust Growth.....III-53
Legislations/Regulatory Policies in Select European Countries.....III-53
1$75
   Legislations Governing Genetic Testing in Select European Countries.....III-541$75
   B. Market Analytics.....III-55
Table 44: European Recent Past, Current & Future Analysis for Genetic Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-55
1$200
   Table 45: European Historic Review for Genetic Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-561$200
   Table 46: European 14-Year Perspective for Genetic Testing by Geographic Region - Percentage Breakdown of Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-571$200
   A. Market Analysis.....III-58
Current & Future Analysis.....III-58
Regulatory Environment in France.....III-58
Elitech Group S.P.A. - A Key Player.....III-58
1$75
   B. Market Analytics.....III-59
Table 47: French Recent Past, Current & Future Analysis for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-59
1$200
   Table 48: French Historic Review for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-601$200
   A. Market Analysis.....III-61
Current & Future Analysis.....III-61
Parliamentary Regulations.....III-61
1$75
   B. Market Analytics.....III-62
Table 49: German Recent Past, Current & Future Analysis for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-62
1$200
   Table 50: German Historic Review for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-631$200
   Market Analysis.....III-64
Table 51: Italian Recent Past, Current & Future Analysis for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-64
1$200
   Table 52: Italian Historic Review for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-651$200
   A. Market Analysis.....III-66
Current & Future Analysis.....III-66
Increased Support for Personalized Medicine to Drive Genetic Testing.....III-66
SMIP for Pharmacogenomic Testing.....III-66
Increasing Need for Less Risky Prenatal Diagnostic Methods in the UK.....III-66
1$75
   Regulatory Scenario.....III-67
Non-consensual Analysis of DNA Made Illegal.....III-67
Principles for DTC Genetic Testing Laid out by HGC.....III-67
1$75
   B. Market Analytics.....III-68
Table 53: The UK Recent Past, Current & Future Analysis for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-68
1$200
   Table 54: The UK Historic Review for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-691$200
   A. Market Analysis.....III-70
Current & Future Analysis.....III-70
Product Launches.....III-70
1$75
   Strategic Corporate Developments.....III-71
Key Players.....III-71
3$225
   B. Market Analytics.....III-74
Table 55: Rest of Europe Recent Past, Current & Future Analysis for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-74
1$200
   Table 56: Rest of Europe Historic Review for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-751$200
   A. Market Analysis.....III-76
Current & Future Analysis.....III-76
Healthcare Spending in Asia-Pacific: On the Rise.....III-76
Select Regional Markets.....III-76
China.....III-76
China’s FDA Curbs Prenatal Testing.....III-76
1$75
   Genetic Testing to Reveal Real Talents in Children – A New Popular
  Application.....III-77
India.....III-77
Diagnostics Market in India.....III-77
1$75
   Genomic Medicine – Nascent yet Promising.....III-78
Genetic Testing in India to Rise.....III-78
1$75
   Australia and New Zealand.....III-79
Approval of Experiments on Human Embryos in New Zealand.....III-79
Product Launches.....III-79
1$75
   Strategic Corporate Developments.....III-801$75
   B. Market Analytics.....III-81
Table 57: Asia-Pacific Recent Past, Current & Future Analysis for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-81
1$200
   Table 58: Asia-Pacific Historic Review for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-821$200
   A. Market Analysis.....III-83
Current & Future Analysis.....III-83
Product/Service Launch.....III-83
Strategic Corporate Development.....III-83
1$75
   B. Market Analytics.....III-84
Table 59: Rest of World Recent Past, Current & Future Analysis for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-84
1$200
   Table 60: Rest of World Historic Review for Genetic Testing Market Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-851$200
  
Total Companies Profiled: 88 (including Divisions/Subsidiaries - 97)

Region/Country Players

The United States 60 Canada 5 Japan 1 Europe 23 France 2 Germany 3 The United Kingdom 2 Spain 1 Rest of Europe 15 Asia-Pacific (Excluding Japan) 5 Middle East 2 Africa 1
Click here to request a full table of contents and more details on this project.